BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante JC, Pons-Romero F. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374-1380. [PMID: 18000721 DOI: 10.1007/s11695-007-9243-7] [Cited by in Crossref: 186] [Cited by in F6Publishing: 180] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 González-Sarrías A, Romo-Vaquero M, García-Villalba R, Cortés-Martín A, Selma MV, Espín JC. The Endotoxemia Marker Lipopolysaccharide-Binding Protein is Reduced in Overweight-Obese Subjects Consuming Pomegranate Extract by Modulating the Gut Microbiota: A Randomized Clinical Trial. Mol Nutr Food Res 2018;62:e1800160. [PMID: 29665619 DOI: 10.1002/mnfr.201800160] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
2 Wong VW, Wong GL, Chan HY, Yeung DK, Chan RS, Chim AM, Chan CK, Tse YK, Woo J, Chu WC. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. Aliment Pharmacol Ther. 2015;42:731-740. [PMID: 26202818 DOI: 10.1111/apt.13327] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
3 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
4 Sogabe M, Okahisa T, Hibino S, Yamanoi A. Usefulness of differentiating metabolic syndrome into visceral fat type and subcutaneous fat type using ultrasonography in Japanese males. J Gastroenterol. 2012;47:293-299. [PMID: 22065161 DOI: 10.1007/s00535-011-0489-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol Ecol 2014;87:303-14. [PMID: 24219358 DOI: 10.1111/1574-6941.12250] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
6 Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
7 Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E699. [PMID: 32151020 DOI: 10.3390/nu12030699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
8 Jin CJ, Engstler AJ, Ziegenhardt D, Bischoff SC, Trautwein C, Bergheim I. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease (NAFLD) in mice. J Gastroenterol Hepatol. 2016; Epub ahead of print. [PMID: 27404046 DOI: 10.1111/jgh.13488] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
9 Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
10 Barengolts E, Green SJ, Chlipala GE, Layden BT, Eisenberg Y, Priyadarshini M, Dugas LR. Predictors of Obesity among Gut Microbiota Biomarkers in African American Men with and without Diabetes. Microorganisms 2019;7:E320. [PMID: 31491976 DOI: 10.3390/microorganisms7090320] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
11 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
12 Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. Diabetes Metab Syndr Obes 2020;13:3861-72. [PMID: 33116732 DOI: 10.2147/DMSO.S249949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Serrano M, Moreno-navarrete JM, Puig J, Moreno M, Guerra E, Ortega F, Xifra G, Ricart W, Fernández-real JM. Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. Atherosclerosis 2013;230:223-7. [DOI: 10.1016/j.atherosclerosis.2013.07.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
14 du Plessis J, Korf H, van Pelt J, Windmolders P, Vander Elst I, Verrijken A, Hubens G, Van Gaal L, Cassiman D, Nevens F, Francque S, van der Merwe S. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. PLoS One 2016;11:e0166048. [PMID: 27992443 DOI: 10.1371/journal.pone.0166048] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
15 Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 2019;12:1756284819858470. [PMID: 31258623 DOI: 10.1177/1756284819858470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
16 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
17 Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
18 Nakano M, Murohisa T, Imai Y, Tamano M, Hiraishi H. Association Between Appendectomy and Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterology Res 2013;6:17-25. [PMID: 27785221 DOI: 10.4021/gr513w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Wang Y, Jiang ZZ, Chen M, Wu MJ, Guo HL, Sun LX, Wang H, Zhang S, Wang T, Zhang LY. Protective effect of total flavonoid C-glycosides from Abrus mollis extract on lipopolysaccharide-induced lipotoxicity in mice. Chin J Nat Med 2014;12:461-8. [PMID: 24969528 DOI: 10.1016/S1875-5364(14)60072-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Sakura T, Morioka T, Shioi A, Kakutani Y, Miki Y, Yamazaki Y, Motoyama K, Mori K, Fukumoto S, Shoji T, Emoto M, Inaba M. Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol 2017;16:62. [PMID: 28486964 DOI: 10.1186/s12933-017-0545-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
21 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
22 Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Archives of Physiology and Biochemistry 2009;115:176-90. [DOI: 10.1080/13813450903079314] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
23 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
24 Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45:543-551. [PMID: 23280158 DOI: 10.1016/j.dld.2012.11.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
25 Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, Xie J, Ji G, Zhu L. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014;29:1292-1298. [PMID: 24372861 DOI: 10.1111/jgh.12510] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
26 Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem. 2011;22:527-534. [PMID: 20801629 DOI: 10.1016/j.jnutbio.2010.04.007] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
27 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Peluso I, Manafikhi H, Reggi R, Palmery M. Effects of red wine on postprandial stress: potential implication in non-alcoholic fatty liver disease development. Eur J Nutr. 2015;54:497-507. [PMID: 25772634 DOI: 10.1007/s00394-015-0877-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
29 Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013;7:880-4. [PMID: 23235292 DOI: 10.1038/ismej.2012.153] [Cited by in Crossref: 346] [Cited by in F6Publishing: 338] [Article Influence: 38.4] [Reference Citation Analysis]
30 Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012;30:149-73. [PMID: 22224779 DOI: 10.1146/annurev-immunol-020711-075001] [Cited by in Crossref: 236] [Cited by in F6Publishing: 233] [Article Influence: 26.2] [Reference Citation Analysis]
31 Banaszewska B, Siakowska M, Chudzicka-Strugala I, Chang RJ, Pawelczyk L, Zwozdziak B, Spaczynski R, Duleba AJ. Elevation of markers of endotoxemia in women with polycystic ovary syndrome. Hum Reprod 2020;35:2303-11. [PMID: 32869098 DOI: 10.1093/humrep/deaa194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kheirandish-Gozal L, Peris E, Wang Y, Tamae Kakazu M, Khalyfa A, Carreras A, Gozal D. Lipopolysaccharide-binding protein plasma levels in children: effects of obstructive sleep apnea and obesity. J Clin Endocrinol Metab 2014;99:656-63. [PMID: 24276451 DOI: 10.1210/jc.2013-3327] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 8.5] [Reference Citation Analysis]
33 Kitabatake H, Tanaka N, Fujimori N, Komatsu M, Okubo A, Kakegawa K, Kimura T, Sugiura A, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Koinuma M, Sano K, Aoyama T, Tanaka E. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(4): 712-722 [PMID: 28216979 DOI: 10.3748/wjg.v23.i4.712] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
34 Fialho A, Fialho A, Kochhar G, Schenone AL, Thota P, McCullough AJ, Shen B. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci 2018;63:412-21. [PMID: 29110161 DOI: 10.1007/s10620-017-4828-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
35 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
36 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 27.0] [Reference Citation Analysis]
37 Liu X, Lu L, Yao P, Ma Y, Wang F, Jin Q, Ye X, Li H, Hu FB, Sun L, Lin X. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese. Diabetologia 2014;57:1834-41. [PMID: 24906952 DOI: 10.1007/s00125-014-3288-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
38 Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G, Hemmat A, Torabi Z. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med 2018;56:85-9. [PMID: 29101772 DOI: 10.1515/rjim-2017-0042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
39 Vansaun MN, Mendonsa AM, Lee Gorden D. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. PLoS One. 2013;8:e73054. [PMID: 24039859 DOI: 10.1371/journal.pone.0073054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
40 Yin X, Peng J, Zhao L, Yu Y, Zhang X, Liu P, Feng Q, Hu Y, Pang X. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol. 2013;36:188-196. [PMID: 23453736 DOI: 10.1016/j.syapm.2012.12.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
41 Sun S, Sun L, Wang K, Qiao S, Zhao X, Hu X, Chen W, Zhang S, Li H, Dai H, Liu H. The gut commensal fungus, Candida parapsilosis, promotes high fat-diet induced obesity in mice. Commun Biol 2021;4:1220. [PMID: 34697386 DOI: 10.1038/s42003-021-02753-3] [Reference Citation Analysis]
42 谢大伟, 刘翠香, 王炳元, 孙福荣, 李金萍, 丁媛媛, 马力, 王振威, 刘畅. 酒精性脂肪性肝病与非酒精性脂肪性肝病的血液生化学检查特点. 世界华人消化杂志 2010; 18(25): 2654-2659 [DOI: 10.11569/wcjd.v18.i25.2654] [Reference Citation Analysis]
43 Keane JM, Khashan AS, McCarthy FP, Kenny LC, Collins JM, O'Donovan S, Brown J, Cryan JF, Dinan TG, Clarke G, O'Mahony SM. Identifying a biological signature of prenatal maternal stress. JCI Insight 2021;6:143007. [PMID: 33301421 DOI: 10.1172/jci.insight.143007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One 2013;8:e54600. [PMID: 23349936 DOI: 10.1371/journal.pone.0054600] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 14.3] [Reference Citation Analysis]
45 Maheshwari G, Gessner DK, Neuhaus K, Most E, Zorn H, Eder K, Ringseis R. Influence of a Biotechnologically Produced Oyster Mushroom ( Pleurotus sajor-caju ) on the Gut Microbiota and Microbial Metabolites in Obese Zucker Rats. J Agric Food Chem 2021;69:1524-35. [DOI: 10.1021/acs.jafc.0c06952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Vespasiani-Gentilucci U, Carotti S, Perrone G, Mazzarelli C, Galati G, Onetti-Muda A, Picardi A, Morini S. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int. 2015;35:569-581. [PMID: 24649857 DOI: 10.1111/liv.12531] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
47 Ilan Y. Immune therapy for nonalcoholic steatohepatitis: are we there yet? J Clin Gastroenterol. 2013;47:298-307. [PMID: 23442833 DOI: 10.1097/mcg.0b013e31827873dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
48 Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. [PMID: 23304111 DOI: 10.1155/2012/107434] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
49 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 21.3] [Reference Citation Analysis]
50 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015;77:245-251. [PMID: 25310763 DOI: 10.1038/pr.2014.157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
51 Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 124] [Article Influence: 22.8] [Reference Citation Analysis]
52 Chávez-tapia NC, González-rodríguez L, Jeong M, López-ramírez Y, Barbero-becerra V, Juárez-hernández E, Romero-flores JL, Arrese M, Méndez-sánchez N, Uribe M. Current evidence on the use of probiotics in liver diseases. Journal of Functional Foods 2015;17:137-51. [DOI: 10.1016/j.jff.2015.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
53 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
54 Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome: Distinction between V- and S-type MS. Hepatol Res 2014;44:515-22. [DOI: 10.1111/hepr.12146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
55 Madupu R, Szpakowski S, Nelson KE. Microbiome in human health and disease. Sci Prog 2013;96:153-70. [PMID: 23901633 DOI: 10.3184/003685013X13683759820813] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
56 Nasr El-Din A, Ata KAE, Abdel-Gawad AR, Fahmy NF. Impact of High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers on Severity of COVID-19 in Obese-Diabetic Patients. Infect Drug Resist 2021;14:4015-25. [PMID: 34611417 DOI: 10.2147/IDR.S329004] [Reference Citation Analysis]
57 Kim KE, Cho YS, Baek KS, Li L, Baek KH, Kim JH, Kim HS, Sheen YH. Lipopolysaccharide-binding protein plasma levels as a biomarker of obesity-related insulin resistance in adolescents. Korean J Pediatr 2016;59:231-8. [PMID: 27279888 DOI: 10.3345/kjp.2016.59.5.231] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
58 Gäbele E, Dostert K, Hofmann C, Wiest R, Schölmerich J, Hellerbrand C, Obermeier F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol. 2011;55:1391-1399. [PMID: 21703208 DOI: 10.1016/j.jhep.2011.02.035] [Cited by in Crossref: 149] [Cited by in F6Publishing: 149] [Article Influence: 14.9] [Reference Citation Analysis]
59 Arieira C, Monteiro S, Xavier S, Dias de Castro F, Magalhães J, Moreira MJ, Marinho C, Cotter J. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. Eur J Gastroenterol Hepatol 2019;31:998-1003. [PMID: 30839437 DOI: 10.1097/MEG.0000000000001319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
61 Kazankov K, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. J Gastroenterol Hepatol 2015;30:1293-300. [PMID: 25772748 DOI: 10.1111/jgh.12943] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
62 Spruss A, Henkel J, Kanuri G, Blank D, Püschel GP, Bischoff SC, Bergheim I. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med. 2012;18:1346-1355. [PMID: 22952059 DOI: 10.2119/molmed.2012.00223] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
63 Suriano F, Neyrinck AM, Verspreet J, Olivares M, Leclercq S, Van de Wiele T, Courtin CM, Cani PD, Bindels LB, Delzenne NM. Particle size determines the anti-inflammatory effect of wheat bran in a model of fructose over-consumption: Implication of the gut microbiota. Journal of Functional Foods 2018;41:155-62. [DOI: 10.1016/j.jff.2017.12.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 5.7] [Reference Citation Analysis]
64 Saghafi-Asl M, Amiri P, Naghizadeh M, Ghavami SM, Karamzad N. Association of endotoxaemia with serum free fatty acids in metabolically healthy and unhealthy abdominally obese individuals: a case-control study in northwest of Iran. BMJ Open 2017;7:e015910. [PMID: 28487462 DOI: 10.1136/bmjopen-2017-015910] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
65 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
66 Schattenberg JM, Czaja MJ. TNF/TNF Receptors. In: Dufour J, Clavien P, editors. Signaling Pathways in Liver Diseases. Berlin: Springer Berlin Heidelberg; 2010. pp. 161-77. [DOI: 10.1007/978-3-642-00150-5_10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23:483-491. [PMID: 23876851 DOI: 10.1016/j.semcancer.2013.07.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 8.9] [Reference Citation Analysis]
68 Mulligan CM, Friedman JE. Maternal modifiers of the infant gut microbiota: metabolic consequences. J Endocrinol 2017;235:R1-R12. [PMID: 28751453 DOI: 10.1530/JOE-17-0303] [Cited by in Crossref: 52] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
69 Aravindhan V, Mohan V, Arunkumar N, Sandhya S, Babu S. Chronic Endotoxemia in Subjects with Type-1 Diabetes Is Seen Much before the Onset of Microvascular Complications. PLoS One 2015;10:e0137618. [PMID: 26367738 DOI: 10.1371/journal.pone.0137618] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
70 Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol 2016;23:132-41. [PMID: 28868449 DOI: 10.1016/j.jpge.2016.01.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
71 Moreno-Navarrete JM, Escoté X, Ortega F, Serino M, Campbell M, Michalski MC, Laville M, Xifra G, Luche E, Domingo P, Sabater M, Pardo G, Waget A, Salvador J, Giralt M, Rodriguez-Hermosa JI, Camps M, Kolditz CI, Viguerie N, Galitzky J, Decaunes P, Ricart W, Frühbeck G, Villarroya F, Mingrone G, Langin D, Zorzano A, Vidal H, Vendrell J, Burcelin R, Vidal-Puig A, Fernández-Real JM. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia 2013;56:2524-37. [PMID: 23963324 DOI: 10.1007/s00125-013-3015-9] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
72 Yang P, Lee W, Tseng P, Lee P, Lin M, Yang W. Bariatric surgery decreased the serum level of an endotoxin-associated marker: lipopolysaccharide-binding protein. Surgery for Obesity and Related Diseases 2014;10:1182-7. [DOI: 10.1016/j.soard.2014.02.022] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
73 Bakker GJ, Zhao J, Herrema H, Nieuwdorp M. Gut Microbiota and Energy Expenditure in Health and Obesity. Journal of Clinical Gastroenterology 2015;49:S13-9. [DOI: 10.1097/mcg.0000000000000363] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
74 Guercio Nuzio S, Di Stasi M, Pierri L, Troisi J, Poeta M, Bisogno A, Belmonte F, Tripodi M, Di Salvio D, Massa G, Savastano R, Cavallo P, Boffardi M, Ziegenhardt D, Bergheim I, Mandato C, Vajro P. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr Obes 2017;12:446-52. [PMID: 27350543 DOI: 10.1111/ijpo.12164] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
75 Akhmedov VA, Gaus OV. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Terapevticheskii arkhiv 2019;91:143-8. [DOI: 10.26442/00403660.2019.02.000051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int 2015;2015:319745. [PMID: 26491664 DOI: 10.1155/2015/319745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
77 Guerra-ruiz A, Casafont F, Cobo M, Terã¡n A, de-la-Peña J, Estebanez A, Pons-romero F. Increased bactericidal/permeability increasing protein in patients with cirrhosis. Liver International 2010;30:94-101. [DOI: 10.1111/j.1478-3231.2009.02121.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
78 de Punder K, Pruimboom L. Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front Immunol 2015;6:223. [PMID: 26029209 DOI: 10.3389/fimmu.2015.00223] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 18.7] [Reference Citation Analysis]
79 Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Hepatol Commun 2018;2:393-406. [PMID: 29619418 DOI: 10.1002/hep4.1165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
80 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Reference Citation Analysis]
81 Nien HC, Hsu SJ, Su TH, Yang PJ, Sheu JC, Wang JT, Chow LP, Chen CL, Kao JH, Yang WS. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. PLoS One 2017;12:e0170028. [PMID: 28107471 DOI: 10.1371/journal.pone.0170028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
82 Lim SM, Jeong JJ, Woo KH, Han MJ, Kim DH. Lactobacillus sakei OK67 ameliorates high-fat diet-induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression. Nutr Res 2016;36:337-48. [PMID: 27001279 DOI: 10.1016/j.nutres.2015.12.001] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 13.5] [Reference Citation Analysis]
83 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Moore T, Globa L, Pustovyy O, Vodyanoy V, Sorokulova I. Oral administration of Bacillus subtilis strain BSB3 can prevent heat stress-related adverse effects in rats. J Appl Microbiol 2014;117:1463-71. [DOI: 10.1111/jam.12606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
85 Sun L, Yu Z, Ye X, Zou S, Li H, Yu D, Wu H, Chen Y, Dore J, Clément K. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care. 2010;33:1925-1932. [PMID: 20530747 DOI: 10.2337/dc10-0340] [Cited by in Crossref: 174] [Cited by in F6Publishing: 166] [Article Influence: 15.8] [Reference Citation Analysis]
86 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
87 Tonan T, Fujimoto K, Qayyum A, Morita Y, Nakashima O, Ono N, Kawahara A, Kage M, Hayabuchi N, Ueno T. CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. J Gastroenterol Hepatol. 2012;27:789-796. [PMID: 22188204 DOI: 10.1111/j.1440-1746.2011.07057.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
88 Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem. 2012;23:203-208. [PMID: 22129639 DOI: 10.1016/j.jnutbio.2011.09.006] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
89 Wang Y, Wang B, Wu J, Jiang X, Tang H, Nielsen OH. Modulation of Gut Microbiota in Pathological States. Engineering 2017;3:83-9. [DOI: 10.1016/j.eng.2017.01.013] [Cited by in Crossref: 16] [Article Influence: 4.0] [Reference Citation Analysis]
90 Pang J, Xu W, Zhang X, Wong GL, Chan AW, Chan H, Tse C, Shu SS, Choi PC, Chan HL, Yu J, Wong VW. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:175-82. [DOI: 10.1111/apt.14119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
91 Citronberg JS, Curtis KR, White E, Newcomb PA, Newton K, Atkinson C, Song X, Lampe JW, Hullar MA. Association of gut microbial communities with plasma lipopolysaccharide-binding protein (LBP) in premenopausal women. ISME J 2018;12:1631-41. [PMID: 29434315 DOI: 10.1038/s41396-018-0064-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
92 Laugerette F, Furet JP, Debard C, Daira P, Loizon E, Géloën A, Soulage CO, Simonet C, Lefils-Lacourtablaise J, Bernoud-Hubac N, Bodennec J, Peretti N, Vidal H, Michalski MC. Oil composition of high-fat diet affects metabolic inflammation differently in connection with endotoxin receptors in mice. Am J Physiol Endocrinol Metab 2012;302:E374-86. [PMID: 22094473 DOI: 10.1152/ajpendo.00314.2011] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 10.2] [Reference Citation Analysis]
93 Spruss A, Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem. 2009;20:657-662. [PMID: 19679262 DOI: 10.1016/j.jnutbio.2009.05.006] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 9.1] [Reference Citation Analysis]
94 De Gottardi A, McCoy KD. Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease. J Hepatol. 2011;55:1181-1183. [PMID: 21703167 DOI: 10.1016/j.jhep.2011.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
95 Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 2018;14:701-6. [PMID: 29765460 DOI: 10.5114/aoms.2016.58831] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
96 Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, Iuliano N, Giordano M, Passariello N, Sasso FC. Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. Infection. 2018;. [PMID: 30066228 DOI: 10.1007/s15010-018-1185-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
97 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 339] [Article Influence: 72.4] [Reference Citation Analysis]
98 Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104. [PMID: 19637282 DOI: 10.1002/hep.23122] [Cited by in Crossref: 352] [Cited by in F6Publishing: 351] [Article Influence: 29.3] [Reference Citation Analysis]
99 Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol. 2010;21:76-83. [PMID: 19915460 DOI: 10.1097/mol.0b013e3283347ebb] [Cited by in Crossref: 116] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
100 Söderberg C, Marmur J, Eckes K, Glaumann H, Sällberg M, Frelin L, Rosenberg P, Stål P, Hultcrantz R. Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. APMIS 2011;119:412-20. [PMID: 21635548 DOI: 10.1111/j.1600-0463.2011.02746.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
101 Jorgačević B, Vučević D, Vesković M, Mladenović D, Vukićević D, Vukićević RJ, Todorović V, Radosavljević T. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease. Can J Physiol Pharmacol 2019;97:120-9. [PMID: 30673308 DOI: 10.1139/cjpp-2018-0607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
102 Adar T, Ben Ya’acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M, Wong V, Muller B, Rawlin G, Ilan Y. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol. 2012;167:252-260. [PMID: 22236001 DOI: 10.1111/j.1365-2249.2011.04511.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
103 Mueller JL, Feeney ER, Zheng H, Misdraji J, Kruger AJ, Alatrakchi N, King LY, Gelrud L, Corey KE, Chung RT. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2015;6:e114. [PMID: 26448455 DOI: 10.1038/ctg.2015.36] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
104 Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645-649. [PMID: 20400911 DOI: 10.1097/mpg.0b013e3181c7bdf1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
105 Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol. 2011;110:650-657. [PMID: 21281408 DOI: 10.1111/j.1365-2672.2010.04922.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 14.0] [Reference Citation Analysis]
106 Guo H, Diao N, Yuan R, Chen K, Geng S, Li M, Li L. Subclinical-Dose Endotoxin Sustains Low-Grade Inflammation and Exacerbates Steatohepatitis in High-Fat Diet-Fed Mice. J Immunol 2016;196:2300-8. [PMID: 26810228 DOI: 10.4049/jimmunol.1500130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
107 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
108 Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients 2020;12:E1082. [PMID: 32295104 DOI: 10.3390/nu12041082] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 44.0] [Reference Citation Analysis]
109 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
110 Pan X, Wen SW, Kaminga AC, Liu A. Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Sci Rep 2020;10:8848. [PMID: 32483129 DOI: 10.1038/s41598-020-65051-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
111 Zhao L, Mehmood A, Yuan D, Usman M, Murtaza MA, Yaqoob S, Wang C. Protective Mechanism of Edible Food Plants against Alcoholic Liver Disease with Special Mention to Polyphenolic Compounds. Nutrients 2021;13:1612. [PMID: 34064981 DOI: 10.3390/nu13051612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18(21): 2609-2618 [PMID: 22690069 DOI: 10.3748/wjg.v18.i21.2609] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 104] [Article Influence: 12.4] [Reference Citation Analysis]
113 Guimarães VM, Santos VN, Borges PSDA, De Farias JLR, Grillo P, Parise ER. PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS. Arq Gastroenterol 2020;57:471-6. [DOI: 10.1590/s0004-2803.202000000-82] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
115 Gutierrez-grobe Y, Villalobos-blasquez I, Sánchez-lara K, Villa AR, Ponciano-rodríguez G, Ramos MH, Chavez-tapia NC, Uribe M, Méndez-sánchez N. High ghrelin and obestatin levels and low risk of developing fatty liver. Annals of Hepatology 2010;9:52-7. [DOI: 10.1016/s1665-2681(19)31679-5] [Cited by in Crossref: 24] [Article Influence: 2.2] [Reference Citation Analysis]
116 Kim AS, Ko HJ. Plasma concentrations of zonulin are elevated in obese men with fatty liver disease. Diabetes Metab Syndr Obes 2018;11:149-57. [PMID: 29719415 DOI: 10.2147/DMSO.S163062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
117 de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017;8:253-267. [PMID: 28609252 DOI: 10.1080/19490976.2017.1293224] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 27.5] [Reference Citation Analysis]
118 Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, Königsrainer A, Bischoff SC, Bergheim I. Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Dig Dis Sci 2012;57:1932-41. [DOI: 10.1007/s10620-012-2112-9] [Cited by in Crossref: 163] [Cited by in F6Publishing: 162] [Article Influence: 18.1] [Reference Citation Analysis]
119 Zimny S, Pohl R, Rein-fischboeck L, Haberl EM, Krautbauer S, Weiss TS, Buechler C. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men. Experimental and Molecular Pathology 2017;103:1-8. [DOI: 10.1016/j.yexmp.2017.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
120 Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H. Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis. Hepatol Res 2018;49:284-95. [DOI: 10.1111/hepr.13281] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
121 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
122 Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11:1693-1700. [PMID: 25421042 DOI: 10.3892/mmr.2014.2995] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
123 戴鑫, 吕宗舜. 肠道屏障功能在非酒精性脂肪性肝病发病机制中的作用. 世界华人消化杂志 2012; 20(8): 656-661 [DOI: 10.11569/wcjd.v20.i8.656] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
124 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701. [PMID: 21045794 DOI: 10.1038/nrgastro.2010.172] [Cited by in Crossref: 298] [Cited by in F6Publishing: 273] [Article Influence: 27.1] [Reference Citation Analysis]
125 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 59.9] [Reference Citation Analysis]
126 Sarna LK, Siow YL, O K. The CBS/CSE system: a potential therapeutic target in NAFLD? Can J Physiol Pharmacol 2015;93:1-11. [PMID: 25493326 DOI: 10.1139/cjpp-2014-0394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
127 Bergheim I, Schuppan D. Microbiome and Diseases: Hepatic Disorders. In: Haller D, editor. The Gut Microbiome in Health and Disease. Cham: Springer International Publishing; 2018. pp. 279-93. [DOI: 10.1007/978-3-319-90545-7_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 黄颖秋. 非酒精性脂肪性肝炎发病机制的研究进展. 世界华人消化杂志 2009; 17(31): 3181-3188 [DOI: 10.11569/wcjd.v17.i31.3181] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
129 Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015;11:e1004559. [PMID: 25625278 DOI: 10.1371/journal.ppat.1004559] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 12.0] [Reference Citation Analysis]
130 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
131 Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, Bridle KR, Anderson GJ, Fletcher LM. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest. 2013;93:1295-1312. [PMID: 24126888 DOI: 10.1038/labinvest.2013.121] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
132 Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Gaïa N, Rubbia-brandt L, Golay A, Schrenzel J, Pichard C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2016;61:2721-31. [DOI: 10.1007/s10620-016-4179-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
133 Tilves CM, Zmuda JM, Kuipers AL, Nestlerode CS, Evans RW, Bunker CH, Patrick AL, Miljkovic I. Association of Lipopolysaccharide-Binding Protein With Aging-Related Adiposity Change and Prediabetes Among African Ancestry Men. Diabetes Care 2016;39:385-91. [PMID: 26721818 DOI: 10.2337/dc15-1777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
134 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
135 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 80] [Article Influence: 13.1] [Reference Citation Analysis]
136 Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-127. [PMID: 23401313 DOI: 10.1002/hep.26319] [Cited by in Crossref: 401] [Cited by in F6Publishing: 376] [Article Influence: 50.1] [Reference Citation Analysis]
137 Shanab AA, Scully P, Crosbie O, Buckley M, O’mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EMM. Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. Dig Dis Sci 2011;56:1524-34. [DOI: 10.1007/s10620-010-1447-3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 116] [Article Influence: 10.8] [Reference Citation Analysis]
138 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
139 Joseph PV, Abey SK, Wang D, Fourie NH, Kenea ND, Vishnyakova TG, Robinson JM, Weaver KR, Boulineaux CM, Davidson HR, Sherwin LB, Ozoji O, Diallo AF, Smyser PA, Patterson AP, Henderson WA. Colon Epithelial MicroRNA Network in Fatty Liver. Can J Gastroenterol Hepatol 2018;2018:8246103. [PMID: 30345259 DOI: 10.1155/2018/8246103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Rouvinen-Watt K, Pal C, Martin T, Harris L, Astatkie T, Kryzskaya D, Kärjä V, Mustonen AM, Tammi R, Tammi M, Nieminen P. Evidence of endoplasmic reticulum stress and liver inflammation in the American mink Neovison vison with benign hepatic steatosis. J Comp Physiol B 2014;184:913-27. [PMID: 25079677 DOI: 10.1007/s00360-014-0845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
141 Machado MV, Cortez-pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:440-9. [DOI: 10.1016/s1665-2681(19)31457-7] [Cited by in Crossref: 99] [Article Influence: 11.0] [Reference Citation Analysis]
142 Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. Curr Obes Rep. 2019;8:317-332. [PMID: 31175629 DOI: 10.1007/s13679-019-00352-2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 71.0] [Reference Citation Analysis]
143 Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, Li M, Sun L, Xue Z, Wang J, Feng J, Yan F, Zhao N, Liu J, Long W, Zhao L. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87:357-367. [PMID: 24117923 DOI: 10.1111/1574-6941.12228] [Cited by in Crossref: 196] [Cited by in F6Publishing: 180] [Article Influence: 24.5] [Reference Citation Analysis]
144 Li L, Li L, Chen L, Lin X, Xu Y, Ren J, Fu J, Qiu Y. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats. J Pharmacol Sci. 2015;127:244-250. [PMID: 25837920 DOI: 10.1016/j.jphs.2014.12.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
145 Peluso I, Palmery M. Risks of misinterpretation in the evaluation of the effect of fruit-based drinks in postprandial studies. Gastroenterol Res Pract 2014;2014:870547. [PMID: 25610461 DOI: 10.1155/2014/870547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
146 Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011;300:G433-G441. [PMID: 21233280 DOI: 10.1152/ajpgi.00163.2009] [Cited by in Crossref: 152] [Cited by in F6Publishing: 156] [Article Influence: 15.2] [Reference Citation Analysis]
147 Laugerette F, Vors C, Alligier M, Pineau G, Drai J, Knibbe C, Morio B, Lambert-Porcheron S, Laville M, Vidal H, Michalski MC. Postprandial Endotoxin Transporters LBP and sCD14 Differ in Obese vs. Overweight and Normal Weight Men during Fat-Rich Meal Digestion. Nutrients 2020;12:E1820. [PMID: 32570947 DOI: 10.3390/nu12061820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 González-Sarrías A, Núñez-Sánchez MA, Ávila-Gálvez MA, Monedero-Saiz T, Rodríguez-Gil FJ, Martínez-Díaz F, Selma MV, Espín JC. Consumption of pomegranate decreases plasma lipopolysaccharide-binding protein levels, a marker of metabolic endotoxemia, in patients with newly diagnosed colorectal cancer: a randomized controlled clinical trial. Food Funct 2018;9:2617-22. [PMID: 29770393 DOI: 10.1039/c8fo00264a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
149 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
150 Scalera A, Di Minno MND, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19(33): 5402-5420 [PMID: 24023483 DOI: 10.3748/wjg.v19.i33.5402] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
151 Ichikawa H, Imoto H, Tanaka N, Fujishima F, Tsuchiya T, Watanabe K, Aoki T, Kohyama A, Morikawa T, Ohnuma S, Naitoh T, Kamei T, Unno M. The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. Surgery 2021:S0039-6060(21)00679-6. [PMID: 34389163 DOI: 10.1016/j.surg.2021.07.003] [Reference Citation Analysis]
152 Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, Adam G, Lavallard VJ, Rovere C, Le Thuc O, Saint-Paul MC, Anty R, Schneck AS, Iannelli A, Gugenheim J, Tran A, Gual P, Bailly-Maitre B. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis 2015;6:e1879. [PMID: 26355342 DOI: 10.1038/cddis.2015.248] [Cited by in Crossref: 162] [Cited by in F6Publishing: 165] [Article Influence: 27.0] [Reference Citation Analysis]
153 Pini M, Rhodes DH, Fantuzzi G. Hematological and acute-phase responses to diet-induced obesity in IL-6 KO mice. Cytokine. 2011;56:708-716. [PMID: 21996012 DOI: 10.1016/j.cyto.2011.09.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
154 Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 2014;15:684-711. [PMID: 24402126 DOI: 10.3390/ijms15010684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
155 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
156 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
157 Aron-wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection 2013;19:338-48. [DOI: 10.1111/1469-0691.12140] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 17.6] [Reference Citation Analysis]
158 Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11:639-647. [PMID: 23912213 DOI: 10.1038/nrmicro3089] [Cited by in Crossref: 412] [Cited by in F6Publishing: 390] [Article Influence: 51.5] [Reference Citation Analysis]
159 Laugerette F, Alligier M, Bastard JP, Drai J, Chanséaume E, Lambert-Porcheron S, Laville M, Morio B, Vidal H, Michalski MC. Overfeeding increases postprandial endotoxemia in men: Inflammatory outcome may depend on LPS transporters LBP and sCD14. Mol Nutr Food Res 2014;58:1513-8. [PMID: 24687809 DOI: 10.1002/mnfr.201400044] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 10.6] [Reference Citation Analysis]
160 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 25.1] [Reference Citation Analysis]
161 Watanabe H, Katsura T, Takahara M, Miyashita K, Katakami N, Matsuoka TA, Kawamori D, Shimomura I. Plasma lipopolysaccharide binding protein level statistically mediates between body mass index and chronic microinflammation in Japanese patients with type 1 diabetes. Diabetol Int 2020;11:293-7. [PMID: 32802711 DOI: 10.1007/s13340-020-00428-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Depommier C, Flamand N, Pelicaen R, Maiter D, Thissen JP, Loumaye A, Hermans MP, Everard A, Delzenne NM, Di Marzo V, Cani PD. Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models. Cells 2021;10:E71. [PMID: 33466285 DOI: 10.3390/cells10010071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
164 Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 2008;15:109-14. [PMID: 18667295 DOI: 10.1016/j.pathophys.2008.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
165 Zhou Y, Wang J, Yang W, Qi X, Lan L, Luo L, Yin Z. Bergapten prevents lipopolysaccharide-induced inflammation in RAW264.7 cells through suppressing JAK/STAT activation and ROS production and increases the survival rate of mice after LPS challenge. Int Immunopharmacol 2017;48:159-68. [PMID: 28511114 DOI: 10.1016/j.intimp.2017.04.026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
166 Ha EK, Kim JH, Yon DK, Lee SW, Kim MA, Lee KS, Sung M, Jee HM, Shin YH, Han MY. Association of serum lipopolysaccharide-binding protein level with sensitization to food allergens in children. Sci Rep 2021;11:2143. [PMID: 33495502 DOI: 10.1038/s41598-020-79241-x] [Reference Citation Analysis]
167 Liang W, Lindeman JH, Menke AL, Koonen DP, Morrison M, Havekes LM, van den Hoek AM, Kleemann R. Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation. Lab Invest 2014;94:491-502. [DOI: 10.1038/labinvest.2014.11] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
168 de Medeiros IC, de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? – A mechanistic hypothesis. Medical Hypotheses 2015;85:148-52. [DOI: 10.1016/j.mehy.2015.04.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
169 Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. [PMID: 23055155 DOI: 10.1002/hep.26093] [Cited by in Crossref: 769] [Cited by in F6Publishing: 739] [Article Influence: 96.1] [Reference Citation Analysis]
170 Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946-953. [PMID: 24018052 DOI: 10.1053/j.gastro.2013.08.058] [Cited by in Crossref: 350] [Cited by in F6Publishing: 304] [Article Influence: 43.8] [Reference Citation Analysis]
171 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
172 Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, Backhed F, Delzenne NM, Schrenzel J, François P, Cani PD. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J 2014;8:2116-30. [PMID: 24694712 DOI: 10.1038/ismej.2014.45] [Cited by in Crossref: 332] [Cited by in F6Publishing: 322] [Article Influence: 47.4] [Reference Citation Analysis]
173 Zhang DY, Zhu L, Liu HN, Tseng YJ, Weng SQ, Liu TT, Dong L, Shen XZ. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. Drug Des Devel Ther 2019;13:2249-70. [PMID: 31308634 DOI: 10.2147/DDDT.S207277] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
174 Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012;2012:694629. [PMID: 22848224 DOI: 10.1155/2012/694629] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
175 Bluemel S, Wang Y, Lee S, Schnabl B. Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World J Gastroenterol 2020; 26(33): 4933-4944 [PMID: 32952340 DOI: 10.3748/wjg.v26.i33.4933] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
177 Asada M, Oishi E, Sakata S, Hata J, Yoshida D, Honda T, Furuta Y, Shibata M, Suzuki K, Watanabe H, Murayama N, Kitazono T, Yamaura K, Ninomiya T. Serum Lipopolysaccharide-Binding Protein Levels and the Incidence of Cardiovascular Disease in a General Japanese Population: The Hisayama Study. J Am Heart Assoc 2019;8:e013628. [PMID: 31657258 DOI: 10.1161/JAHA.119.013628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
178 Hansen ME, Simmons KJ, Tippetts TS, Thatcher MO, Saito RR, Hubbard ST, Trumbull AM, Parker BA, Taylor OJ, Bikman BT. Lipopolysaccharide Disrupts Mitochondrial Physiology in Skeletal Muscle via Disparate Effects on Sphingolipid Metabolism. Shock 2015;44:585-92. [PMID: 26529656 DOI: 10.1097/SHK.0000000000000468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
179 Nien HC, Sheu JC, Chi YC, Chen CL, Kao JH, Yang WS. One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis. PLoS One. 2018;13:e0207882. [PMID: 30458048 DOI: 10.1371/journal.pone.0207882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
180 Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santibañez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-κB and AP-1 DNA Binding in Obese Patients. Obesity 2009;17:973-9. [DOI: 10.1038/oby.2008.601] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 7.2] [Reference Citation Analysis]